A study to evaluate the effects of BGF and GFF on Specific Image based Airway Volumes and Resistance in Subjects with Moderate to Severe COPD

Study identifier:D5980C00019

ClinicalTrials.gov identifier:NCT03836677

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-blind, Two Treatment, Two Period, Chronic dosing (4 weeks), Crossover, Multi-center Pilot study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate and Glycopyrronium/Formoterol Fumarate on Specific Image based Airway Volumes and Resistance in Subjects with Moderate to Severe COPD

Medical condition

Chronic obstructive pulmonary disease (COPD)

Phase

Phase 3

Healthy volunteers

No

Study drug

BGF, GFF

Sex

All

Actual Enrollment

23

Study type

Interventional

Age

40 Years - 80 Years

Date

Study Start Date: 26 Feb 2019
Primary Completion Date: 11 Nov 2019
Study Completion Date: 11 Nov 2019

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria